close

American Oriental Bioengineering, Inc., along with its subsidiaries, engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products. It offers prescription and over-the-counter pharmaceutical products, and nutraceutical products. The company's prescription pharmaceutical products include Shuanghuanlian Lyophilized (SHL) injection powder, an anti-viral injection for the treatment of flu symptoms, upper respiratory infections, mild pneumonia, and tonsillitis; and Cease Enuresis Soft Gel (CE Gel) to alleviate pediatric bedwetting. American Oriental Bioengineering markets the SHL products under SHJ brand name; the CE Gel under the brand name, Three Happines; and AOBO-001, an oral capsule developed from traditional Chinese herbal medicine for the treatment of urinary incontinence, which is in the phase one clinical trial. Its over-the-counter pharmaceutical products comprise Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS), and other PMS and menopause-related symptoms; and Boke nasal spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. The company's nutraceutical products include soybean peptide based drinks, tablets, powder, and instant coffee for health and well-being. American Oriental Bioengineering sells its products primarily to hospitals, clinics, pharmacies, and retail outlets in China. The company is based in Shenzhen, the People's Republic of China.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.58
Volume	(mio) 1.02
Volume Avg	111682
52 Week High	7.96
52 Week Low	1.11
PE	3.94
PE (group average)	39
EPS Year	0.34
EPS change Q/Q	-75%
EPS change Q/Q Yr ago	-75%
EPS change Q/Q next Q est	-83.33%
EPS change Y/Y	189.47%
REV change Q/Q	-37.65%
REV change Q/Q Yr ago	-3.17%
EPS next Q est	0.06
EPS next Y est	0.30
Divident Annual	0.00
Dividend Yield	0%